Pershing Square CEO Bill Ackman has apologized to clients for the firm’s $4 billion debacle with Canadian pharmaceuticals company Valeant Pharmaceuticals, describing the investment a “huge mistake” and taking responsibility for misjudging both Valeant’s management and its aggressive acquisition strategy.